CST | Jotup

C3 Industries Broadens Footprint with Opening of First High Profile Cannabis Dispensary in Illinois, 23rd Retail Location Nationwide

Retrieved on:

Tuesday, February 6, 2024

Cannabis, C3, University, Recreation, High roller, High, Action Park, High Profile, Veteran, ANN, CST, Retail

ANN ARBOR, Mich., Feb. 6, 2024 /PRNewswire/ -- C3 Industries ("C3" or "the Company"), a leading multi-state cannabis company dedicated to crafting premium cannabis experiences for consumers, has expanded its operational footprint with the opening of its first retail location in Illinois, High Profile Springfield, and its 23rd dispensary nationwide. The new retail location is now open, serving cannabis consumers 21 years and older daily in-store and through its convenient online pre-order and curbside pickup services. To celebrate its opening, High Profile Springfield is offering customers 15% off on their first visit and 10% off on their second visit, along with the best everyday pricing and discounts relative to the competition in the area and ample, convenient parking access.

Key Points:

High Profile Springfield Is Now Serving Cannabis Consumers Daily from 8:00 a.m. to 9:00 p.m. CST from Hometown of Abraham Lincoln; Highly Convenient,
ANN ARBOR, Mich., Feb. 6, 2024 /PRNewswire/ -- C 3 Industries ("C3" or "the Company"), a leading multi-state cannabis company dedicated to crafting premium cannabis experiences for consumers, has expanded its operational footprint with the opening of its first retail location in Illinois, High Profile Springfield , and its 23rd dispensary nationwide.
The new retail location is now open, serving cannabis consumers 21 years and older daily in-store and through its convenient online pre-order and curbside pickup services.
In addition, C3 announced it will host High Profile Springfield's official grand opening celebration on Friday, February 9, 2024 at 4:20 p.m. CST, which will feature product specials, vendor tables and food trucks.
"The opening of our 23rd dispensary nationwide reinforces our commitment to serving communities with high-quality, accessible cannabis offerings in a welcoming space where customers can feel educated, supported and valued.

Medtronic to announce financial results for its third quarter of fiscal year 2024

Retrieved on:

Tuesday, February 6, 2024

News, Webcast, CST, Medtronic, Central Time Zone

DUBLIN, Feb. 6, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2024 on Tuesday, February 20, 2024.

Key Points:

DUBLIN, Feb. 6, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2024 on Tuesday, February 20, 2024.
The news release will include summary financial information for the company's third quarter of fiscal year 2024, which ended on Friday, January 26, 2024.
Medtronic will host a video webcast at 7:00 a.m. CST on Tuesday, February 20, 2024, to discuss results for its third quarter of fiscal year 2024.
Looking ahead, Medtronic plans to report its fiscal year 2024 fourth quarter results on Thursday, May 23, 2024.

ArcBest Announces Fourth Quarter and Full Year 2023 Results

Retrieved on:

Tuesday, February 6, 2024

ArcBest® (Nasdaq: ARCB), a leader in supply chain logistics, today reported fourth quarter 2023 revenue from continuing operations of $1.1 billion, compared to $1.2 billion in the fourth quarter of 2022.

Key Points:

ArcBest® (Nasdaq: ARCB), a leader in supply chain logistics, today reported fourth quarter 2023 revenue from continuing operations of $1.1 billion, compared to $1.2 billion in the fourth quarter of 2022.
“2023 was a milestone year for ArcBest as we celebrated our 100-year anniversary and again delivered solid financial results,” said Judy R. McReynolds, ArcBest chairman, president and CEO.
Cost control actions, initiated in the third quarter of 2023 also positively contributed to the fourth quarter Asset-Based operating ratio.
ArcBest will host a conference call with company executives to discuss the fourth quarter and full year 2023 results.

Seadrill Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Retrieved on:

Monday, February 5, 2024

Oil, Gas, Energy, Machinery, Engineering, Maritime, Logistics, Supply Chain Management, Transport, Manufacturing, The Company, CST, SDRL

February 5, 2024-- Seadrill Limited ("Seadrill" or the "Company") (NYSE & OSE: SDRL) will report its fourth quarter and full year 2023 results on Wednesday, February 28, 2024 after the NYSE closes for trading.

Key Points:

February 5, 2024-- Seadrill Limited ("Seadrill" or the "Company") (NYSE & OSE: SDRL) will report its fourth quarter and full year 2023 results on Wednesday, February 28, 2024 after the NYSE closes for trading.
The Company will host a conference call to discuss its results on Thursday, February 29, 2024 at 09:00 CST / 16:00 CET.
Interested participants may join the call by dialing +1 (888) 660-6819 (Passcode: 7310670) at least 15 minutes prior to the scheduled start time.
The Company will also webcast the call live on its website, www.seadrill.com/investors , where a replay will be available afterwards.

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Retrieved on:

Saturday, February 3, 2024

This result confirms that the positive visual and anatomical outcomes from our Phase 2 DAVIO 2 trial were driven by EYP-1901 and not by supplemental injections.

Key Points:

This result confirms that the positive visual and anatomical outcomes from our Phase 2 DAVIO 2 trial were driven by EYP-1901 and not by supplemental injections.
A second presentation also included the previously reported positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901.
DAVIO 2 is a randomized, controlled Phase 2 clinical trial of EYP-1901 in previously treated patients with wet AMD.
Phase 2 DAVIO 2 12-month results and the initiation of a Phase 3 trial in wet AMD are both expected in the second half of 2024.

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

Retrieved on:

Saturday, February 3, 2024

Data presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference by Arshad M. Khanani, M.D., M.A., FASRS, consisted of 24-week landmark results from the randomized Phase 2 Dose Expansion cohort of the PRISM clinical trial.

Key Points:

Data presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference by Arshad M. Khanani, M.D., M.A., FASRS, consisted of 24-week landmark results from the randomized Phase 2 Dose Expansion cohort of the PRISM clinical trial.
"I am encouraged by the potential of a one-time intravitreal injection of 4D-150 for treating wet AMD.
Results from the Phase 1 and interim results from Phase 2 cohorts of the PRISM study confirm that 4D-150 is well tolerated and maintains stable visual acuity in previously treated high-need patients.
I believe 4D-150 has the potential to revolutionize the treatment approach for our patients with wet AMD, and I am looking forward to participating in the Phase 3 trials."

Brunswick Corporation Releases 2023 Fourth Quarter & Full Year Earnings

Retrieved on:

Thursday, February 1, 2024

Telephone, CST, EST, Access, Internet, Form, Brunswick Corporation, Online shopping

METTAWA, Ill., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Brunswick Corporation (NYSE: BC), today, released its fourth quarter and full year 2023 financial results.

Key Points:

METTAWA, Ill., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Brunswick Corporation (NYSE: BC), today, released its fourth quarter and full year 2023 financial results.
A complete and full-text financial results press release is available on the Company’s website at https://ir.brunswick.com .
The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1 .
A copy of the presentation to be used on this call will be available when the results are released as noted above.

Skyward Specialty to Host Fourth-Quarter 2023 Earnings Call Wednesday, February 21, 2024

Retrieved on:

Wednesday, January 31, 2024

PIN, CST

HOUSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.™ (NASDAQ: SKWD) ("Skyward Specialty" or "the Company") expects to issue its fourth-quarter 2023 earnings results after the market closes on Tuesday, February 20, which will be available on the Company website at investors.skywardinsurance.com/ under Quarterly Results.

Key Points:

HOUSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.™ (NASDAQ: SKWD) ("Skyward Specialty" or "the Company") expects to issue its fourth-quarter 2023 earnings results after the market closes on Tuesday, February 20, which will be available on the Company website at investors.skywardinsurance.com/ under Quarterly Results.
Skyward Specialty will host its earnings call to review fourth-quarter 2023 financial results on Wednesday, February 21, at 9 a.m. CST.
Investors may access the live audio webcast via the link on the Company’s investor site at investors.skywardinsurance.com/ under Events & Presentations.
A webcast replay will be available two hours following the call in the same location on the Company’s investor website.

Valaris Schedules Fourth Quarter 2023 Earnings Release and Conference Call

Retrieved on:

Wednesday, January 31, 2024

Maritime, Energy, Transport, Oil, Gas, Limited, EST, CST

Valaris Limited (NYSE: VAL) ("Valaris" or the "Company") will hold its fourth quarter 2023 earnings conference call at 9:00 a.m. CST (10:00 a.m. EST) on Thursday, February 22, 2024.

Key Points:

Valaris Limited (NYSE: VAL) ("Valaris" or the "Company") will hold its fourth quarter 2023 earnings conference call at 9:00 a.m. CST (10:00 a.m. EST) on Thursday, February 22, 2024.
The earnings release will be issued before the New York Stock Exchange opens that morning.
Valaris uses its website to disclose material and non-material information to investors, customers, employees and others interested in the Company.
To receive regular updates on Valaris news or SEC filings, please sign-up for Email Alerts on the Company’s website.

Q1 2024 Insurance Labor Market Study Results to be Highlighted in Webinar

Retrieved on:

Wednesday, January 31, 2024

Finance, Banking, Professional Services, Insurance, Human Resources, Intelligence, Environment, Aon (company), AON, CST

The results of the Q1 2024 Insurance Labor Market Study will be shared in a complimentary webinar presentation at 1 p.m. CST on February 8, 2024.

Key Points:

The results of the Q1 2024 Insurance Labor Market Study will be shared in a complimentary webinar presentation at 1 p.m. CST on February 8, 2024.
The semi-annual study was conducted by The Jacobson Group , the leading provider of talent to the insurance industry, and Aon plc (NYSE: AON), a leading global professional services firm.
The survey ran from January 8 through January 30, and surveyed insurance carriers across all industry sectors on hiring and revenue plans for the coming year.
"For 15 years, the results of this study have served as a benchmark for insurers as they fine-tune their talent strategies,” said Jacobson.